No adverse effects of adjuvant chemotherapy on hippocampal volumein Japanese breast cancer survivors

Yoshikawa, Eisho; Matsuoka, Yutaka; Inagaki, Masumi; Nakano, Tomohito; Akechi, Tatsuo; Kobayakawa, Makoto; Fujimori, Maiko; Nakaya, Naoki; Akizuki, Nobuya; Imoto, Shigeru; Murakami, Koji; Uchitomi, Yosuke

doi:10.1007/s10549-005-1412-6

Cited by 56 publications

(55 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in line with the absence of large differences between chemotherapyexposed survivors and the general population more than 20 years post-treatment that we observed. The only other study that investigated the association between hippocampal volume and chemotherapy did also not observe a relationship between the two [8]. Of all studies that investigated the effect of chemotherapy on brain structure, none examined total tissue volumes after cytotoxic treatment [2][3][4][7][8][9][10].…”

Section: Discussionmentioning

confidence: 99%

“…This was not observed in another group of patients who were 3 years post-treatment [7]. A study that strictly examined hippocampal volume did not find differences between cancer patients who received chemotherapy 3 years before and those who did not [8]. We recently showed that breast cancer survivors who completed high-dose chemotherapy almost 10 years before had less focal gray matter than survivors who never received chemotherapy [4].…”

Section: Introductionmentioning

confidence: 88%

“…Their sample sizes were relatively small: the number of chemotherapy-exposed patients ranged from 5 to73 (Table 1) [ [2][3][4][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy

Koppelmans

Ruiter

Lijn

et al. 2011

Breast Cancer Res Treat

150

113

View full text Add to dashboard Cite

A limited number of studies have associated adjuvant chemotherapy with structural brain changes. These studies had small sample sizes and were conducted shortly after cessation of chemotherapy. Results of these studies indicate local gray matter volume decrease and an increase in white matter lesions. Up till now, it is unclear if non-CNS chemotherapy is associated with long-term structural brain changes. We compared focal and total brain volume (TBV) of a large set of non-CNS directed chemotherapy-exposed breast cancer survivors, on average 21 years post-treatment, to that of a population-based sample of women without a history of cancer. Structural MRI (1.5T) was performed in 184 chemotherapy-exposed breast cancer patients, mean age 64.0 (SD = 6.5) years, who had been diagnosed with cancer on average 21.1 (SD = 4.4) years before, and 368 age-matched cancer-free reference subjects from a population-based cohort study. Outcome measures were: TBV and total gray and white matter volume, and hippocampal volume. In addition, voxel based morphometry was performed to analyze differences in focal gray matter. The chemotherapy-exposed breast cancer survivors had significantly smaller TBV (-3.5 ml, P = 0.019) and gray matter volume (-2.9 ml, P = 0.003) than the reference subjects. No significant differences were observed in white matter volume, hippocampal volume, or local gray matter volume. This study shows that adjuvant chemotherapy for breast cancer is associated with long-term reductions in TBV and overall gray matter volume in the absence of focal reductions. The observed smaller gray matter volume in chemotherapy- 123Breast Cancer Res Treat (2012) 132:1099-1106 DOI 10.1007/s10549-011-1888-1 exposed survivors was comparable to the effect of almost 4 years of age on gray matter volume reduction. These volume differences might be associated with the slightly worse cognitive performance that we observed previously in this group of breast cancer survivors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 88%

See 1 more Smart Citation

Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy

Koppelmans

Ruiter

Lijn

et al. 2011

Breast Cancer Res Treat

150

113

View full text Add to dashboard Cite

show abstract

“…Gray and white matter volume loss as well as hippocampal atrophy have been described in association with some chemotherapeutic treatments (Schneiderman 2004;Saykin et al 2003;Madhyastha et al 2002). However, these findings have not always been replicated (Yoshikawa et al 2005) suggesting the need for further investigation.…”

Section: Neuroimaging and Neurophysiologic Correlates Of Chemotherapymentioning

confidence: 99%

Neuropsychological Sequelae of Non-Central Nervous System Cancer and Cancer Therapy

2008

View full text Add to dashboard Cite

Cancer patients report numerous adverse symptoms associated with their disease and treatment including cognitive dysfunction, fatigue, and affective distress. Cognitive dysfunction is ubiquitous in patients with primary central nervous system (CNS) cancer and recent evidence has documented similar deficits in patients with non-CNS cancer as well. Both the cancer itself and treatments including chemotherapy, biological response modifiers, and hormonal therapies have been demonstrated to adversely impact cognitive and neurobehavioral function. Neuroimaging and neurophysiological investigations have likewise revealed alterations in brain function that are helping to account for the nature of these cognitive disorders. Similarly, preclinical animal research is assisting to identify the pathophysiological mechanisms that underlie treatment-related neurotoxicities. The coalescence of multidisciplinary clinical and research efforts hold promise for the development of interventions that may offer neuroprotection in addition to currently available symptomatic therapies and cognitive rehabilitation techniques.

show abstract

“…30,31 Although the first study did not find any significant chemotherapy-related difference in hippocampal volume, 30 volume differences in the cingulate gyrus, superior and middle frontal gyri, parahippocampal gyrus and precuneus were observed at one (but not three) years. There is also a fascinating and rare, study of twins.…”

Section: Neuroimaging Studiesmentioning

confidence: 88%

Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment

Raffa

2010

Chemo Fog

View full text Add to dashboard Cite

T he chemotherapy-related cognitive impairment (chemo fog/chemo brain) that is reported by many cancer patients is supported to varying degrees primarily by evidence from prospective and retrospective clinical studies. However, the inherent difficulty in conducting such trials (including ethical issues of placebo-controlled designs), the fact that the cognitive impairment is characteristically subtle and that the patients might be able to compensate for their deficits during testing, gives rise to questions about the degree and the extent of the problem-and indeed even if there is a problem. Neuroimaging techniques might offer additional insight. This chapter is a succinct summary of a more expanded review of the relatively few such studies.

show abstract

No adverse effects of adjuvant chemotherapy on hippocampal volumein Japanese breast cancer survivors

Cited by 56 publications

References 15 publications

Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy

Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy

Neuropsychological Sequelae of Non-Central Nervous System Cancer and Cancer Therapy

Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment

Contact Info

Product

Resources

About